Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment

被引:24
作者
Dowell, James A. [1 ]
Marbury, Thomas C. [2 ]
Smith, William B. [3 ]
Henkel, Tim [4 ]
机构
[1] Pharmacol Dev Serv LLC, Collegeville, PA USA
[2] Orlando Clin Res Ctr, Orlando, FL USA
[3] Univ Tennessee, Med Ctr, Knoxville, TN USA
[4] Venatotx Pharmaceut Inc, Malvern, PA 19355 USA
基金
美国国家卫生研究院;
关键词
taniborbactam; cefepime; cefepime-taniborbactam; VNRX-5133; beta-lactamase inhibitor; drug safety; pharmacokinetics; renal impairment; EQUATION; DISEASE; DIET;
D O I
10.1128/aac.00253-22
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Taniborbactam, an investigational beta-lactamase inhibitor that is active against both serine- and metallo-beta-lactamases, is being developed in combination with cefepime to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Anticipating the use of cefepime-taniborbactam in patients with impaired renal function, an open-label, single-dose clinical study was performed to examine the pharmacokinetics of both drugs in subjects with various degrees of renal function. Hemodialysis-dependent subjects were also studied to examine the amounts of cefepime and taniborbactam dialyzed. Single intravenous infusions of 2 g cefepime and 0.5 g taniborbactam coadministered over 2 h were examined, with hemodialysis-dependent subjects receiving doses both on- and off-dialysis. No subjects experienced serious adverse events or discontinued treatment due to adverse events. The majority of adverse events observed were mild in severity, and there were no trends in the safety of cefepime-taniborbactam related to declining renal function or the timing of hemodialysis. Clinically significant and similar decreases in drug clearance with declining renal function were observed for both cefepime and taniborbactam. The respective decreases in geometric mean clearance for subjects with mild, moderate, and severe renal impairment compared to subjects with normal renal function were 18%, 63%, and 78% for cefepime and 15%, 63%, and 81% for taniborbactam, respectively. Decreases in clearance were similar for both drugs and were shown to be proportional to decreases in renal function. Both cefepime and taniborbactam were dialyzable, with similar amounts removed during 4 h of hemodialysis. This study is registered at ClinicalTrials.gov as NCT03690362.
引用
收藏
页数:10
相关论文
共 22 条
[1]   In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria [J].
Abdelraouf, Kamilia ;
Abuhussain, Safa Almarzoky ;
Nicolau, David P. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (12) :3601-3610
[2]  
[Anonymous], 2010, GUID IND PHARM PAT I
[3]  
[Anonymous], 2012, MAXIPIME (cefepime hydrochloride, USP for injection)
[4]   SAFETY, TOLERANCE, AND PHARMACOKINETIC EVALUATION OF CEFEPIME AFTER ADMINISTRATION OF SINGLE INTRAVENOUS DOSES [J].
BARBHAIYA, RH ;
FORGUE, ST ;
GLEASON, CR ;
KNUPP, CA ;
PITTMAN, KA ;
WEIDLER, DJ ;
MARTIN, RR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (06) :1118-1122
[5]   PHARMACOKINETICS OF CEFEPIME IN SUBJECTS WITH RENAL-INSUFFICIENCY [J].
BARBHAIYA, RH ;
KNUPP, CA ;
FORGUE, ST ;
MATZKE, GR ;
GUAY, DRP ;
PITTMAN, KA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (03) :268-276
[6]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[7]  
Daigle DM., 2018, ABSTR 28 TH EUR CONG
[8]   Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor [J].
Dowell, James A. ;
Dickerson, Daniel ;
Henkel, Tim .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (11)
[9]  
Geibel B., 2019, ABSTR 29 TH EUR CONG
[10]  
Georgiou P-C., 2018, ABSTR P1540 ABSTR 28